Your issue is the assumption that RC110 isn’t up to scratch. It was made commercially redundant by an in house innovation. Thats how successful companies operate, they iterate and disrupt internally.
There is a wealth of data on the clinical application of RC110 for haematological malignancies. Halfway through development we became aware that there are applications in solid tumors. Now there was a crossroad, continue RC110, or develop a solution that could target solid tumors.
The choice was made, and we’re yet to see if that was the right decision or not. But misrepresenting RC110 as ineffective or as clinically inadequate are a bit disingenuous and I would hazard a guess that you know that.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-148
-
- There are more pages in this discussion • 244 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |